Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Drops By 7.5%

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 20,830,000 shares, a decrease of 7.5% from the October 15th total of 22,530,000 shares. Based on an average daily volume of 1,950,000 shares, the short-interest ratio is currently 10.7 days.

BioCryst Pharmaceuticals Trading Up 0.4 %

Shares of NASDAQ BCRX opened at $7.06 on Tuesday. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $8.88. The firm has a market capitalization of $1.46 billion, a PE ratio of -11.57 and a beta of 1.89. The firm has a fifty day simple moving average of $7.69 and a two-hundred day simple moving average of $7.18.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same quarter last year, the company posted ($0.19) earnings per share. The firm’s revenue for the quarter was up 35.1% compared to the same quarter last year. On average, sell-side analysts predict that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Deerfield Management Company L.P. Series C increased its stake in shares of BioCryst Pharmaceuticals by 62.9% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after acquiring an additional 3,140,804 shares in the last quarter. Kynam Capital Management LP increased its stake in shares of BioCryst Pharmaceuticals by 41.9% in the 1st quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock worth $33,160,000 after acquiring an additional 1,927,491 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after acquiring an additional 127,708 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after acquiring an additional 481,359 shares in the last quarter. Finally, Two Sigma Advisers LP increased its stake in shares of BioCryst Pharmaceuticals by 13.6% in the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after acquiring an additional 261,500 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. JMP Securities upped their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a report on Tuesday, August 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.67.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.